Alienor/ENGOT-ov7 randomized trial exploring weekly paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian sex cord tumors (SCT) in relapse
| Autor: | Jalid Sehouli, U. De Giorgi, Andreas Schnelzer, Laurence Gladieff, A. Lesoin, Hans-Joachim Lueck, Salvatore Antonio Pignata, G. Mangili, C. Dalban, I.L. Ray-Coquard, Domenica Lorusso, Magali Provansal, Keiichi Fujiwara, Patricia Pautier, Pierre-Etienne Heudel, P. Harter, Fabien Brocard, Anne Floquet, Frédéric Selle, Ignace Vergote |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Bevacizumab business.industry Ovarian sex cord tumors Weekly paclitaxel Hematology law.invention 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine Paclitaxel chemistry Randomized controlled trial law 030220 oncology & carcinogenesis Internal medicine medicine business medicine.drug |
| Zdroj: | Annals of Oncology. 29:viii333 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdy285.143 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|